NDAORALTABLET
Approved
Jan 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
LODINE (etodolac) by Pfizer is clinical pharmacology pharmacodynamics etodolac is a nonsteroidal anti-inflammatory drug (nsaid) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. First approved in 1991.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LODINE (etodolac) is an oral nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthetase to deliver anti-inflammatory, analgesic, and antipyretic effects. It is indicated for rheumatoid arthritis, acute pain, and post-operative pain management. The drug is a racemic mixture with the [+]S-enantiomer conferring biological activity and achieving 100% bioavailability with peak plasma concentrations in approximately 80 minutes.
LOE Approaching
As LOE approaches, LODINE team will shift focus from growth initiatives to lifecycle extension, patient retention, and managed decline—signaling smaller commercial teams and reduced promotional headcount.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of etodolac, like that of other NSAIDs, is not completely understood, but may be related…
Worked on LODINE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.